Lung transplant infection

Respirology

Volumn 18, Issue 1, 2013, Pages 22-38

  Burguete, Sergio R ^a   Maselli, Diego J ^a   Fernandez, Juan F ^a   Levine, Stephanie M ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Aspergillus; bacterial pneumonia; cytomegalovirus; immunosuppression; lung transplantation

Indexed keywords

ALEMTUZUMAB; AMANTADINE; AMINOGLYCOSIDE; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; AZATHIOPRINE; BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN A; ECHINOCANDIN; EVEROLIMUS; FOSCARNET; GANCICLOVIR; ITRACONAZOLE; OKT 3; RIBAVIRIN; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR; VORICONAZOLE; ZANAMIVIR;

ACUTE GRAFT REJECTION; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIGEN DETECTION; ASPERGILLUS; ATYPICAL MYCOBACTERIUM; BACTERIAL COLONIZATION; BACTERIAL PNEUMONIA; BACTERIAL SUPERINFECTION; BLOOD CULTURE; BRONCHIOLITIS OBLITERANS; BRONCHOSCOPY; BURKHOLDERIA CENOCEPACIA; CANDIDIASIS; CAUSE OF DEATH; CELLULAR IMMUNITY; CHRONIC GRAFT REJECTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CILIARY MOTILITY; CLINICAL FEATURE; COCCIDIOIDOMYCOSIS; CONCURRENT INFECTION; CYTOMEGALOVIRUS INFECTION; DENERVATION; DIARRHEA; DISEASE PREDISPOSITION; GRAFT INFECTION; GRAFT RECIPIENT; GRAFT SURVIVAL; HISTOPLASMOSIS; HUMAN; HUMAN METAPNEUMOVIRUS; IMMUNOCOMPROMISED PATIENT; IMMUNOGLOBULIN DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INFLUENZA; INFLUENZA VACCINATION; INTERSTITIAL LUNG DISEASE; LONG TERM SURVIVAL; LUNG ASPERGILLOSIS; LUNG GRAFT REJECTION; LUNG INFECTION; LUNG LAVAGE; LUNG TRANSPLANTATION; LYMPHATIC DRAINAGE; MORBIDITY; MORTALITY; MYCOBACTERIUM ABSCESSUS; NAUSEA; NONHUMAN; OPPORTUNISTIC INFECTION; PARAMYXOVIRUS INFECTION; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PULMONARY CRYPTOCOCCOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; RISK REDUCTION; SURVIVAL RATE; TRACHEOBRONCHITIS; TREATMENT DURATION; VIRUS INFECTION; VIRUS PNEUMONIA;

BACTERIAL INFECTIONS; GRAFT REJECTION; HUMANS; LUNG; LUNG DISEASES; LUNG TRANSPLANTATION; MYCOSES; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; VIRUS DISEASES;

EID: 84871833576     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2012.02196.x     Document Type: Review

References (160)

1. Chmiel C, Speich R, Hofer M, et al,. Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation. Clin. Infect. Dis. 2008; 46: 831-9.
2. Speich R, van der Bij W,. Epidemiology and management of infections after lung transplantation. Clin. Infect. Dis. 2001; 33 (Suppl. 1): S58-65.
3. Parada MT, Alba A, Sepulveda C,. Early and late infections in lung transplantation patients. Transplant. Proc. 2010; 42: 333-5.
4. Levine SM,. ACCP Pulm Crit Care Update. 1999; 13:lesson 16.
5. Christie JD, Edwards LB, Kucheryavaya AY, et al,. The registry of the international society for heart and lung transplantation: twenty-eighth adult lung and heart-lung transplant report-2011. J. Heart Lung Transplant. 2011; 30: 1104-22.
6. Parada MT, Alba A, Sepulveda C,. Bronchiolitis obliterans syndrome development in lung transplantation patients. Transplant. Proc. 2010; 42: 331-2.
7. Cook DJ, Kollef MH,. Risk factors for ICU-acquired pneumonia. JAMA 1998; 279: 1605-6.
8. Desmond P, Raman R, Idikula J,. Effect of nasogastric tubes on the nose and maxillary sinus. Crit. Care Med. 1991; 19: 509-11.
9. Verleden GM, Vos R, van Raemdonck D, et al,. Pulmonary infection defense after lung transplantation: does airway ischemia play a role? Curr. Opin. Organ. Transplant. 2010; 15: 568-71.
10. Norgaard MA, Andersen CB, Pettersson G,. Airway epithelium of transplanted lungs with and without direct bronchial artery revascularization. Eur. J. Cardiothorac Surg. 1999; 15: 37-44.
11. Gade J, Qvortrup K, Andersen CB, et al,. Bronchial transsection and reanastomosis in pigs with and without bronchial arterial circulation. Ann. Thorac. Surg. 2001; 71: 332-6.
12. Murthy SC, Gildea TR, Machuzak MS,. Anastomotic airway complications after lung transplantation. Curr. Opin. Organ. Transplant. 2010; 15: 582-7.
13. Bhorade SM, Stern E,. Immunosuppression for lung transplantation. Proc. Am. Thorac. Soc. 2009; 6: 47-53.
14. Floreth T, Bhorade SM,. Current trends in immunosuppression for lung transplantation. Semin. Respir. Crit. Care Med. 2010; 31: 172-8.
15. Floreth T, Bhorade SM, Ahya VN,. Conventional and novel approaches to immunosuppression. Clin. Chest Med. 2011; 32: 265-77.
16. Parekh K, Trulock E, Patterson GA,. Use of cyclosporine in lung transplantation. Transplant. Proc. 2004; 36 (Suppl. 2): 318S-22S.
17. Staatz CE, Tett SE,. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin. Pharmacokinet. 2007; 46: 13-58.
18. Terada N, Lucas JJ, Szepesi A, et al,. Rapamycin blocks cell cycle progression of activated T cells prior to events characteristic of the middle to late G1 phase of the cycle. J. Cell. Physiol. 1993; 154: 7-15.
19. Saunders RN, Metcalfe MS, Nicholson ML,. Rapamycin in transplantation: a review of the evidence. Kidney Int. 2001; 59: 3-16.
20. Kirchner GI, Meier-Wiedenbach I, Manns MP,. Clinical pharmacokinetics of everolimus. Clin. Pharmacokinet. 2004; 43: 83-95.
21. Barnes PJ,. Corticosteroid effects on cell signalling. Eur. Respir. J. 2006; 27: 413-26.
22. de la Torre M, Pena E, Calvin M, et al,. Basiliximab in lung transplantation: preliminary experience. Transplant. Proc. 2005; 37: 1534-6.
23. Flaman F, Zieroth S, Rao V, et al,. Basiliximab versus rabbit anti-thymocyte globulin for induction therapy in patients after heart transplantation. J. Heart Lung Transplant. 2006; 25: 1358-62.
24. Johnson MR, Mullen GM, O'Sullivan EJ, et al,. Risk/benefit ratio of perioperative OKT3 in cardiac transplantation. Am. J. Cardiol. 1994; 74: 261-6.
25. Smart FW, Naftel DC, Costanzo MR, et al,. Risk factors for early, cumulative, and fatal infections after heart transplantation: a multiinstitutional study. J. Heart Lung Transplant. 1996; 15: 329-41.
26. Segovia J, Rodriguez-Lambert JL, Crespo-Leiro MG, et al,. A randomized multicenter comparison of basiliximab and muromonab (OKT3) in heart transplantation: SIMCOR study. Transplantation 2006; 81: 1542-8.
27. Brock MV, Borja MC, Ferber L, et al,. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti-thymocyte globulin, and daclizumab. J. Heart Lung Transplant. 2001; 20: 1282-90.
28. Anonymous Organ Procurement and Transplantation Network (OPTN), Scientific Registry of Transplant Recipients (SRTR). OPTN/SRTR 2010 Annual Data Report. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, Rockville, MD, 2011, 117.
29. Cai J, Terasaki PI,. Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: an analysis of United Network for Organ Sharing registry data. Transplantation 2010; 90: 1511-15.
30. Di Filippo S, Boissonnat P, Sassolas F, et al,. Rabbit antithymocyte globulin as induction immunotherapy in pediatric heart transplantation. Transplantation 2003; 75: 354-8.
31. Hachem RR, Edwards LB, Yusen RD, et al,. The impact of induction on survival after lung transplantation: an analysis of the International Society for Heart and Lung Transplantation Registry. Clin. Transplant. 2008; 22: 603-8.
32. Clinckart F, Bulpa P, Jamart J, et al,. Basiliximab as an alternative to antithymocyte globulin for early immunosuppression in lung transplantation. Transplant. Proc. 2009; 41: 607-9.
33. Shyu S, Dew MA, Pilewski JM, et al,. Five-year outcomes with alemtuzumab induction after lung transplantation. J. Heart Lung Transplant. 2011; 30: 743-54.
34. Campos S, Caramori M, Teixeira R, et al,. Bacterial and fungal pneumonias after lung transplantation. Transplant. Proc. 2008; 40: 822-4.
35. Dobbin C, Maley M, Harkness J, et al,. The impact of pan-resistant bacterial pathogens on survival after lung transplantation in cystic fibrosis: results from a single large referral centre. J. Hosp. Infect. 2004; 56: 277-82.
36. Hadjiliadis D, Steele MP, Chaparro C, et al,. Survival of lung transplant patients with cystic fibrosis harboring panresistant bacteria other than Burkholderia cepacia, compared with patients harboring sensitive bacteria. J. Heart Lung Transplant. 2007; 26: 834-8.
37. Murray S, Charbeneau J, Marshall BC, et al,. Impact of Burkholderia infection on lung transplantation in cystic fibrosis. Am. J. Respir. Crit. Care Med. 2008; 178: 363-71.
38. Alexander BD, Petzold EW, Reller LB, et al,. Survival after lung transplantation of cystic fibrosis patients infected with Burkholderia cepacia complex. Am. J. Transplant. 2008; 8: 1025-30.
39. Boussaud V, Guillemain R, Grenet D, et al,. Clinical outcome following lung transplantation in patients with cystic fibrosis colonised with Burkholderia cepacia complex: results from two French centres. Thorax 2008; 63: 732-7.
40. Nash EF, Coonar A, Kremer R, et al,. Survival of Burkholderia cepacia sepsis following lung transplantation in recipients with cystic fibrosis. Transpl. Infect. Dis. 2010; 12: 551-4.
41. Fischer SA, Avery RK, Infectious AST,. Disease community of practice. screening of donor and recipient prior to solid organ transplantation. Am. J. Transplant. 2009; 9 (Suppl. 4): S7-18.
42. Avlonitis VS, Krause A, Luzzi L, et al,. Bacterial colonization of the donor lower airways is a predictor of poor outcome in lung transplantation. Eur. J. Cardiothorac Surg. 2003; 24: 601-7.
43. Orens JB, Boehler A, de Perrot M, et al,. A review of lung transplant donor acceptability criteria. J. Heart Lung Transplant. 2003; 22: 1183-200.
44. Bonde PN, Patel ND, Borja MC, et al,. Impact of donor lung organisms on post-lung transplant pneumonia. J. Heart Lung Transplant. 2006; 25: 99-105.
45. Weill D, Dey GC, Hicks RA, et al,. A positive donor gram stain does not predict outcome following lung transplantation. J. Heart Lung Transplant. 2002; 21: 555-8.
46. King CS, Khandhar S, Burton N, et al,. Native lung complications in single-lung transplant recipients and the role of pneumonectomy. J. Heart Lung Transplant. 2009; 28: 851-6.
47. Aguilar-Guisado M, Givalda J, Ussetti P, et al,. Pneumonia after lung transplantation in the RESITRA Cohort: a multicenter prospective study. Am. J. Transplant. 2007; 7: 1989-96.
48. de Bruyn G, Whelan TP, Mulligan MS, et al,. Invasive pneumococcal infections in adult lung transplant recipients. Am. J. Transplant. 2004; 4: 1366-71.
49. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 2005; 171: 388-416.
50. Snyder LD, Finlen-Copeland CA, Turbyfill WJ, et al,. Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation. Am. J. Respir. Crit. Care Med. 2010; 181: 1391-6.
51. Humar A, Snydman D, Infectious AST,. Diseases community of practice. Cytomegalovirus in solid organ transplant recipients. Am. J. Transplant. 2009; 9 (Suppl. 4): S78-86.
52. Zamora MR,. Cytomegalovirus and lung transplantation. Am. J. Transplant. 2004; 4: 1219-26.
53. Kotton CN, Kumar D, Caliendo AM, et al,. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89: 779-95.
54. Humar A, Michaels M, AST ID Working Group on Infectious Disease Monitoring. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am. J. Transplant. 2006; 6: 262-74.
55. Zuk DM, Humar A, Weinkauf JG, et al,. An international survey of cytomegalovirus management practices in lung transplantation. Transplantation 2010; 90: 672-6.
56. Lisboa LF, Kumar D, Wilson LE, et al,. Clinical Utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia. Transplantation 2012; 93: 195-200.
57. Kumar D, Chernenko S, Moussa G, et al,. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am. J. Transplant. 2009; 9: 1214-22.
58. Hodson EM, Craig JC, Strippoli GF, et al,. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst. Rev. 2008; (2): CD003774.
59. Jaksch P, Zweytick B, Kerschner H, et al,. Cytomegalovirus prevention in high-risk lung transplant recipients: comparison of 3- vs 12-month valganciclovir therapy. J. Heart Lung Transplant. 2009; 28: 670-5.
60. Snydman DR, Limaye AP, Potena L, et al,. Update and review: state-of-the-art management of cytomegalovirus infection and disease following thoracic organ transplantation. Transplant. Proc. 2011; 43 (Suppl. 3): S1-17.
61. Palmer SM, Limaye AP, Banks M, et al,. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann. Intern. Med. 2010; 152: 761-9.
62. Asberg A, Humar A, Rollag H, et al,. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am. J. Transplant. 2007; 7: 2106-13.
63. Kumar D, Husain S, Chen MH, et al,. A prospective molecular surveillance study evaluating the clinical impact of community-acquired respiratory viruses in lung transplant recipients. Transplantation 2010; 89: 1028-33.
64. Kumar D, Morris MI, Kotton CN, et al,. Guidance on novel influenza A/H1N1 in solid organ transplant recipients. Am. J. Transplant. 2010; 10: 18-25.
65. Khalifah AP, Hachem RR, Chakinala MM, et al,. Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am. J. Respir. Crit. Care Med. 2004; 170: 181-7.
66. Garantziotis S, Howell DN, McAdams HP, et al,. Influenza pneumonia in lung transplant recipients: clinical features and association with bronchiolitis obliterans syndrome. Chest 2001; 119: 1277-80.
67. Vilchez R, McCurry K, Dauber J, et al,. Influenza and parainfluenza respiratory viral infection requiring admission in adult lung transplant recipients. Transplantation 2002; 73: 1075-8.
68. Danziger-Isakov LA, Husain S, Mooney ML, et al,. The novel 2009 H1N1 influenza virus pandemic: unique considerations for programs in cardiothoracic transplantation. J. Heart Lung Transplant. 2009; 28: 1341-7.
69. Sims KD, Blumberg EA,. Common infections in the lung transplant recipient. Clin. Chest Med. 2011; 32: 327-41.
70. Faix DJ, Sherman SS, Waterman SH,. Rapid-test sensitivity for novel swine-origin influenza A (H1N1) virus in humans. N. Engl. J. Med. 2009; 361: 728-9.
71. Centers for Disease Control and Prevention (CDC). Pneumonia and influenza death rates-United States, 1979-1994. MMWR Morb. Mortal. Wkly Rep. 1995; 44: 535-7.
72. Ison MG, Michaels MG, Infectious AST,. Diseases community of practice. RNA respiratory viral infections in solid organ transplant recipients. Am. J. Transplant. 2009; 9 (Suppl. 4): S166-72.
73. Ison MG,. Respiratory viral infections in transplant recipients. Antivir. Ther. 2007; 12 (4 Pt B): 627-38.
74. Kim YJ, Boeckh M, Englund JA,. Community respiratory virus infections in immunocompromised patients: hematopoietic stem cell and solid organ transplant recipients, and individuals with human immunodeficiency virus infection. Semin. Respir. Crit. Care Med. 2007; 28: 222-42.
75. Sparrelid E, Ljungman P, Ekelof-Andstrom E, et al,. Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections. Bone Marrow Transplant. 1997; 19: 905-8.
76. Liu V, Dhillon GS, Weill D,. A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients. Transpl. Infect. Dis. 2010; 12: 38-44.
77. Glanville AR, Scott AI, Morton JM, et al,. Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation. J. Heart Lung Transplant. 2005; 24: 2114-19.
78. Pelaez A, Lyon GM, Force SD, et al,. Efficacy of oral ribavirin in lung transplant patients with respiratory syncytial virus lower respiratory tract infection. J. Heart Lung Transplant. 2009; 28: 67-71.
79. Shah PD, McDyer JF,. Viral infections in lung transplant recipients. Semin. Respir. Crit. Care Med. 2010; 31: 243-54.
80. Weinberg A, Lyu DM, Li S, et al,. Incidence and morbidity of human metapneumovirus and other community-acquired respiratory viruses in lung transplant recipients. Transpl. Infect. Dis. 2010; 12: 330-5.
81. Sole A, Salavert M,. Fungal infections after lung transplantation. Curr. Opin. Pulm. Med. 2009; 15: 243-53.
82. Singh N, Husain S, Infectious AST,. Diseases community of practice. Invasive aspergillosis in solid organ transplant recipients. Am. J. Transplant. 2009; 9 (Suppl. 4): S180-91.
83. Danziger-Isakov LA, Worley S, Arrigain S, et al,. Increased mortality after pulmonary fungal infection within the first year after pediatric lung transplantation. J. Heart Lung Transplant. 2008; 27: 655-61.
84. Singh N, Husain S,. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J. Heart Lung Transplant. 2003; 22: 258-66.
85. Ruiz I, Gavalda J, Monforte V, et al,. Donor-to-host transmission of bacterial and fungal infections in lung transplantation. Am. J. Transplant. 2006; 6: 178-82.
86. Luong ML, Morrissey O, Husain S,. Assessment of infection risks prior to lung transplantation. Curr. Opin. Infect. Dis. 2010; 23: 578-83.
87. Pappas PG, Alexander BD, Andes DR, et al,. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin. Infect. Dis. 2010; 50: 1101-11.
88. Minari A, Husni R, Avery RK, et al,. The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants. Transpl. Infect. Dis. 2002; 4: 195-200.
89. Gordon SM, Avery RK,. Aspergillosis in lung transplantation: incidence, risk factors, and prophylactic strategies. Transpl. Infect. Dis. 2001; 3: 161-7.
90. Avery RK,. Infections after lung transplantation. Semin. Respir. Crit. Care Med. 2006; 27: 544-51.
91. Avery RK,. Antifungal prophylaxis in lung transplantation. Semin. Respir. Crit. Care Med. 2011; 32: 717-26.
92. Singh N, Paterson DL,. Aspergillus infections in transplant recipients. Clin. Microbiol. Rev. 2005; 18: 44-69.
93. Helmi M, Love RB, Welter D, et al,. Aspergillus infection in lung transplant recipients with cystic fibrosis: risk factors and outcomes comparison to other types of transplant recipients. Chest 2003; 123: 800-8.
94. Husain S, Paterson DL, Studer SM, et al,. Aspergillus galactomannan antigen in the bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in lung transplant recipients. Transplantation 2007; 83: 1330-6.
95. Walsh TJ, Wissel MC, Grantham KJ, et al,. Molecular detection and species-specific identification of medically important Aspergillus species by real-time PCR in experimental invasive pulmonary aspergillosis. J. Clin. Microbiol. 2011; 49: 4150-7.
96. Alexander BD, Smith PB, Davis RD, et al,. The (1,3){beta}-D-glucan test as an aid to early diagnosis of invasive fungal infections following lung transplantation. J. Clin. Microbiol. 2010; 48: 4083-8.
97. Hosseini-Moghaddam SM, Husain S,. Fungi and molds following lung transplantation. Semin. Respir. Crit. Care Med. 2010; 31: 222-33.
98. Herbrecht R, Denning DW, Patterson TF, et al,. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 2002; 347: 408-15.
99. Walsh TJ, Anaissie EJ, Denning DW, et al,. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 2008; 46: 327-60.
100. Berge M, Guillemain R, Boussaud V, et al,. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients. Transpl. Infect. Dis. 2009; 11: 211-19.
101. Palmer SM, Alexander BD, Sanders LL, et al,. Significance of blood stream infection after lung transplantation: analysis in 176 consecutive patients. Transplantation 2000; 69: 2360-6.
102. Sole A, Salavert M,. Fungal infections after lung transplantation. Transplant. Rev. (Orlando) 2008; 22: 89-104.
103. Pappas PG, Silveira FP, Infectious AST,. Diseases Community of Practice. Candida in solid organ transplant recipients. Am. J. Transplant. 2009; 9 (Suppl. 4): S173-9.
104. Wheat LJ,. Approach to the diagnosis of invasive aspergillosis and candidiasis. Clin. Chest Med. 2009; 30: 367-77. viii.
105. Wheat LJ, Kauffman CA,. Histoplasmosis. Infect. Dis. Clin. North Am. 2003; 17: 1-19. vii.
106. Cuellar-Rodriguez J, Avery RK, Lard M, et al,. Histoplasmosis in solid organ transplant recipients: 10 years of experience at a large transplant center in an endemic area. Clin. Infect. Dis. 2009; 49: 710-16.
107. Miller MB, Hendren R, Gilligan PH,. Posttransplantation disseminated coccidioidomycosis acquired from donor lungs. J. Clin. Microbiol. 2004; 42: 2347-9.
108. Singh N, Forrest G, Infectious AST,. Diseases Community of Practice. Cryptococcosis in solid organ transplant recipients. Am. J. Transplant. 2009; 9 (Suppl. 4): S192-8.
109. Kontoyiannis DP, Lewis RE, Alexander BD, et al,. Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis. Antimicrob. Agents Chemother. 2008; 52: 735-8.
110. Singh N, Lortholary O, Alexander BD, et al,. An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. Clin. Infect. Dis. 2005; 40: 1756-61.
111. Ambrosioni J, Bouchuiguir-Wafa K, Garbino J,. Emerging invasive zygomycosis in a tertiary care center: epidemiology and associated risk factors. Int. J. Infect. Dis. 2010; 14 (Suppl. 3): e100-3.
112. Silveira FP, Husain S,. Fungal infections in lung transplant recipients. Curr. Opin. Pulm. Med. 2008; 14: 211-18.
113. McGuire FR, Grinnan DC, Robbins M,. Mucormycosis of the bronchial anastomosis: a case of successful medical treatment and historic review. J. Heart Lung Transplant. 2007; 26: 857-61.
114. Cadena J, Levine DJ, Angel LF, et al,. Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients: hepatotoxicity and effectiveness. Am. J. Transplant. 2009; 9: 2085-91.
115. Dummer JS, Lazariashvilli N, Barnes J, et al,. A survey of anti-fungal management in lung transplantation. J. Heart Lung Transplant. 2004; 23: 1376-81.
116. Monforte V, Ussetti P, Lopez R, et al,. Nebulized liposomal amphotericin B prophylaxis for Aspergillus infection in lung transplantation: pharmacokinetics and safety. J. Heart Lung Transplant. 2009; 28: 170-5.
117. Monforte V, Ussetti P, Gavalda J, et al,. Feasibility, tolerability, and outcomes of nebulized liposomal amphotericin B for Aspergillus infection prevention in lung transplantation. J. Heart Lung Transplant. 2010; 29: 523-30.
118. Palmer SM, Drew RH, Whitehouse JD, et al,. Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation 2001; 72: 545-8.
119. Sole A,. Invasive fungal infections in lung transplantation: role of aerosolised amphotericin B. Int. J. Antimicrob. Agents 2008; 32 (Suppl. 2): S161-5.
120. Husain S, Paterson DL, Studer S, et al,. Voriconazole prophylaxis in lung transplant recipients. Am. J. Transplant. 2006; 6: 3008-16.
121. Capitano B, Potoski BA, Husain S, et al,. Intrapulmonary penetration of voriconazole in patients receiving an oral prophylactic regimen. Antimicrob. Agents Chemother. 2006; 50: 1878-80.
122. Dromer C, Nashef SA, Velly JF, et al,. Tuberculosis in transplanted lungs. J. Heart Lung Transplant. 1993; 12 (6 Pt 1): 924-7.
123. Malouf MA, Glanville AR,. The spectrum of mycobacterial infection after lung transplantation. Am. J. Respir. Crit. Care Med. 1999; 160 (5 Pt 1): 1611-16.
124. Chalermskulrat W, Sood N, Neuringer IP, et al,. Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation. Thorax 2006; 61: 507-13.
125. Taylor JL, Palmer SM,. Mycobacterium abscessus chest wall and pulmonary infection in a cystic fibrosis lung transplant recipient. J. Heart Lung Transplant. 2006; 25: 985-8.
126. Gilljam M, Schersten H, Silverborn M, et al,. Lung transplantation in patients with cystic fibrosis and Mycobacterium abscessus infection. J. Cyst. Fibros. 2010; 9: 272-6.
127. Chernenko SM, Humar A, Hutcheon M, et al,. Mycobacterium abscessus infections in lung transplant recipients: the international experience. J. Heart Lung Transplant. 2006; 25: 1447-55.
128. Garrison AP, Morris MI, Doblecki Lewis S, et al,. Mycobacterium abscessus infection in solid organ transplant recipients: report of three cases and review of the literature. Transpl. Infect. Dis. 2009; 11: 541-8.
129. Doucette K, Fishman JA,. Nontuberculous mycobacterial infection in hematopoietic stem cell and solid organ transplant recipients. Clin. Infect. Dis. 2004; 38: 1428-39.
130. Griffith DE, Aksamit T, Brown-Elliott BA, et al,. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am. J. Respir. Crit. Care Med. 2007; 175: 367-416.
131. Santacruz JF, Mehta AC,. Airway complications and management after lung transplantation: ischemia, dehiscence, and stenosis. Proc. Am. Thorac. Soc. 2009; 6: 79-93.
132. Sole A, Morant P, Salavert M, et al,. Aspergillus infections in lung transplant recipients: risk factors and outcome. Clin. Microbiol. Infect. 2005; 11: 359-65.
133. Hamacher J, Spiliopoulos A, Kurt AM, et al,. Pre-emptive therapy with azoles in lung transplant patients. Geneva Lung Transplantation Group. Eur. Respir. J. 1999; 13: 180-6.
134. Palmer SM, Perfect JR, Howell DN, et al,. Candidal anastomotic infection in lung transplant recipients: successful treatment with a combination of systemic and inhaled antifungal agents. J. Heart Lung Transplant. 1998; 17: 1029-33.
135. Hadjiliadis D, Howell DN, Davis RD, et al,. Anastomotic infections in lung transplant recipients. Ann. Transplant. 2000; 5 (3): 13-19.
136. Rodriguez M, Fishman JA,. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin. Microbiol. Rev. 2004; 17: 770-82.
137. Arend SM, Westendorp RG, Kroon FP, et al,. Rejection treatment and cytomegalovirus infection as risk factors for Pneumocystis carinii pneumonia in renal transplant recipients. Clin. Infect. Dis. 1996; 22: 920-5.
138. Arthurs SK, Eid AJ, Deziel PJ, et al,. The impact of invasive fungal diseases on survival after lung transplantation. Clin. Transplant. 2010; 24: 341-8.
139. Subramanian AK,. Antimicrobial prophylaxis regimens following transplantation. Curr. Opin. Infect. Dis. 2011; 24: 344-9.
140. Thomas CF, Jr, Limper AH,. Pneumocystis pneumonia. N. Engl. J. Med. 2004; 350: 2487-98.
141. Gordon SM, LaRosa SP, Kalmadi S, et al,. Should prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients ever be discontinued? Clin. Infect. Dis. 1999; 28: 240-6.
142. Ritter ML, Pirofski L,. Mycophenolate mofetil: effects on cellular immune subsets, infectious complications, and antimicrobial activity. Transpl. Infect. Dis. 2009; 11: 290-7.
143. Oz HS, Hughes WT,. Novel anti-Pneumocystis carinii effects of the immunosuppressant mycophenolate mofetil in contrast to provocative effects of tacrolimus, sirolimus, and dexamethasone. J. Infect. Dis. 1997; 175: 901-4.
144. Sollinger HW, Belzer FO, Deierhoi MH, et al,. RS-61443 (mycophenolate mofetil). A multicenter study for refractory kidney transplant rejection. Ann. Surg. 1992; 216: 513-18. Discussion 518-19.
145. The Mycophenolate Mofetil Renal Refractory Rejection Study Group. Anonymous mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. Transplantation 1996; 61: 722-9.
146. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Anonymous A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029-37.
147. Khan BA, Duncan M, Reynolds J, et al,. Nocardia infection in lung transplant recipients. Clin. Transplant. 2008; 22: 562-6.
148. Martinez R, Reyes S, Menendez R,. Pulmonary nocardiosis: risk factors, clinical features, diagnosis and prognosis. Curr. Opin. Pulm. Med. 2008; 14: 219-27.
149. Christie JD, Carby M, Bag R, et al,. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part II: definition. A consensus statement of the International Society for Heart and Lung Transplantation. J. Heart Lung Transplant. 2005; 24: 1454-9.
150. Estenne M, Maurer JR, Boehler A, et al,. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J. Heart Lung Transplant. 2002; 21: 297-310.
151. Valentine VG, Gupta MR, Walker JE, Jr, et al,. Effect of etiology and timing of respiratory tract infections on development of bronchiolitis obliterans syndrome. J. Heart Lung Transplant. 2009; 28: 163-9.
152. Botha P, Archer L, Anderson RL, et al,. Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome. Transplantation 2008; 85: 771-4.
153. Vos R, Vanaudenaerde BM, Verleden SE, et al,. A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation. Eur. Respir. J. 2011; 37: 164-72.
154. Vos R, Vanaudenaerde BM, Ottevaere A, et al,. Long-term azithromycin therapy for bronchiolitis obliterans syndrome: divide and conquer? J. Heart Lung Transplant. 2010; 29: 1358-68.
155. Gottlieb J, Mattner F, Weissbrodt H, et al,. Impact of graft colonization with gram-negative bacteria after lung transplantation on the development of bronchiolitis obliterans syndrome in recipients with cystic fibrosis. Respir. Med. 2009; 103: 743-9.
156. Verleden GM, Dupont LJ,. Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2004; 77: 1465-7.
157. Glanville AR, Gencay M, Tamm M, et al,. Chlamydia pneumoniae infection after lung transplantation. J. Heart Lung Transplant. 2005; 24: 131-6.
158. Kotsimbos TC, Snell GI, Levvey B, et al,. Chlamydia pneumoniae serology in donors and recipients and the risk of bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2005; 79: 269-75.
159. Weigt SS, Elashoff RM, Huang C, et al,. Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome. Am. J. Transplant. 2009; 9: 1903-11.
160. Valentine VG, Bonvillain RW, Gupta MR, et al,. Infections in lung allograft recipients: ganciclovir era. J. Heart Lung Transplant. 2008; 27: 528-35.